Aileron Property Plant And Equipment Gross vs Net Debt Analysis

ALRN Stock

USD 3.77 0.08 2.08%

Aileron Therapeutics financial indicator trend analysis is way more than just evaluating Aileron Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aileron Therapeutics is a good investment. Please check the relationship between Aileron Therapeutics Property Plant And Equipment Gross and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.

Property Plant And Equipment Gross vs Net Debt

Property Plant And Equipment Gross vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aileron Therapeutics Property Plant And Equipment Gross account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Aileron Therapeutics' Property Plant And Equipment Gross and Net Debt is -0.1. Overlapping area represents the amount of variation of Property Plant And Equipment Gross that can explain the historical movement of Net Debt in the same time period over historical financial statements of Aileron Therapeutics, assuming nothing else is changed. The correlation between historical values of Aileron Therapeutics' Property Plant And Equipment Gross and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Gross of Aileron Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Property Plant And Equipment Gross i.e., Aileron Therapeutics' Property Plant And Equipment Gross and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.1

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Property Plant And Equipment Gross

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Aileron Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aileron Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.As of the 18th of May 2024, Enterprise Value is likely to grow to about 92.6 M, while Selling General Administrative is likely to drop about 10.8 K.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	26.6M	27.6M	15.2M	24.4M
Cost Of Revenue	121K	169K	119K	113.1K

Total Operating Expenses Cost Of Revenue

Aileron Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Short Term Investments	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Non Current Liabilities Total	Property Plant And Equipment Gross
Total Assets		0.51	0.45	0.48	0.63	0.55	-0.71	0.22	0.45	-0.27	0.32	-0.07	0.65	0.24	0.4	0.53	0.33	0.76	-0.14	-0.13	0.92	0.94	0.43	0.71	0.16	-0.08
Other Current Liab	0.51		0.69	0.66	0.69	0.67	-0.59	0.53	0.45	0.34	0.51	0.26	0.66	0.4	0.6	0.36	0.52	0.52	0.07	0.1	0.27	0.34	-0.2	0.44	-0.39	0.13
Total Current Liabilities	0.45	0.69		0.78	0.83	0.78	-0.64	0.71	0.36	0.28	0.48	0.25	0.79	0.5	0.72	0.2	0.49	0.45	0.54	0.57	0.22	0.29	-0.34	0.35	-0.58	0.59
Total Stockholder Equity	0.48	0.66	0.78		0.96	1.0	-0.77	0.51	-0.02	-0.1	0.63	0.54	0.93	0.71	0.92	-0.18	0.65	0.64	0.27	0.3	0.27	0.27	-0.44	0.58	-0.79	0.33
Other Liab	0.63	0.69	0.83	0.96		0.97	-0.89	0.58	0.14	-0.1	0.48	0.29	0.99	0.64	0.93	0.06	0.49	0.76	0.26	0.29	0.47	0.48	-0.31	0.69	-0.64	0.33
Net Tangible Assets	0.55	0.67	0.78	1.0	0.97		-0.81	0.5	0.02	-0.12	0.61	0.49	0.95	0.7	0.91	-0.12	0.63	0.68	0.25	0.27	0.35	0.35	-0.38	0.63	-0.74	0.31
Retained Earnings	-0.71	-0.59	-0.64	-0.77	-0.89	-0.81		-0.49	-0.16	0.27	-0.28	-0.06	-0.94	-0.52	-0.89	-0.29	-0.3	-0.95	-0.02	-0.04	-0.64	-0.64	0.2	-0.92	0.37	-0.09
Accounts Payable	0.22	0.53	0.71	0.51	0.58	0.5	-0.49		0.55	0.1	0.38	0.09	0.55	0.24	0.54	0.17	0.38	0.34	0.25	0.27	-0.02	0.09	-0.47	0.25	-0.43	0.29
Cash	0.45	0.45	0.36	-0.02	0.14	0.02	-0.16	0.55		0.15	0.12	-0.3	0.12	-0.21	-0.04	0.65	0.11	0.15	-0.07	-0.06	0.29	0.43	0.23	0.06	0.33	-0.05
Other Assets	-0.27	0.34	0.28	-0.1	-0.1	-0.12	0.27	0.1	0.15		-0.12	-0.12	-0.17	-0.34	-0.16	0.3	-0.14	-0.4	0.45	0.46	-0.32	-0.25	-0.01	-0.44	-0.08	0.45
Cash And Short Term Investments	0.32	0.51	0.48	0.63	0.48	0.61	-0.28	0.38	0.12	-0.12		0.86	0.43	0.52	0.43	-0.19	1.0	0.31	-0.08	-0.07	-0.04	-0.01	-0.38	0.27	-0.48	-0.06
Short Term Investments	-0.07	0.26	0.25	0.54	0.29	0.49	-0.06	0.09	-0.3	-0.12	0.86		0.25	0.54	0.37	-0.57	0.87	0.08	-0.01	0.0	-0.36	-0.39	-0.58	0.08	-0.66	0.0
Capital Surpluse	0.65	0.66	0.79	0.93	0.99	0.95	-0.94	0.55	0.12	-0.17	0.43	0.25		0.65	0.94	0.1	0.45	0.82	0.19	0.22	0.52	0.52	-0.3	0.76	-0.6	0.26
Other Current Assets	0.24	0.4	0.5	0.71	0.64	0.7	-0.52	0.24	-0.21	-0.34	0.52	0.54	0.65		0.69	-0.32	0.56	0.45	0.11	0.12	0.1	0.06	-0.49	0.41	-0.64	0.14
Other Stockholder Equity	0.4	0.6	0.72	0.92	0.93	0.91	-0.89	0.54	-0.04	-0.16	0.43	0.37	0.94	0.69		-0.08	0.45	0.77	0.23	0.26	0.27	0.25	-0.55	0.74	-0.75	0.3
Total Liab	0.53	0.36	0.2	-0.18	0.06	-0.12	-0.29	0.17	0.65	0.3	-0.19	-0.57	0.1	-0.32	-0.08		-0.21	0.34	-0.23	-0.21	0.55	0.63	0.43	0.29	0.56	-0.19
Total Current Assets	0.33	0.52	0.49	0.65	0.49	0.63	-0.3	0.38	0.11	-0.14	1.0	0.87	0.45	0.56	0.45	-0.21		0.32	-0.08	-0.06	-0.04	-0.01	-0.4	0.28	-0.5	-0.05
Common Stock	0.76	0.52	0.45	0.64	0.76	0.68	-0.95	0.34	0.15	-0.4	0.31	0.08	0.82	0.45	0.77	0.34	0.32		-0.2	-0.19	0.7	0.69	-0.08	0.99	-0.18	-0.13
Property Plant Equipment	-0.14	0.07	0.54	0.27	0.26	0.25	-0.02	0.25	-0.07	0.45	-0.08	-0.01	0.19	0.11	0.23	-0.23	-0.08	-0.2		1.0	-0.14	-0.12	-0.08	-0.23	-0.41	1.0
Property Plant And Equipment Net	-0.13	0.1	0.57	0.3	0.29	0.27	-0.04	0.27	-0.06	0.46	-0.07	0.0	0.22	0.12	0.26	-0.21	-0.06	-0.19	1.0		-0.14	-0.12	-0.11	-0.21	-0.44	1.0
Net Debt	0.92	0.27	0.22	0.27	0.47	0.35	-0.64	-0.02	0.29	-0.32	-0.04	-0.36	0.52	0.1	0.27	0.55	-0.04	0.7	-0.14	-0.14		0.99	0.61	0.68	0.33	-0.1
Non Current Assets Total	0.94	0.34	0.29	0.27	0.48	0.35	-0.64	0.09	0.43	-0.25	-0.01	-0.39	0.52	0.06	0.25	0.63	-0.01	0.69	-0.12	-0.12	0.99		0.6	0.65	0.35	-0.08
Non Currrent Assets Other	0.43	-0.2	-0.34	-0.44	-0.31	-0.38	0.2	-0.47	0.23	-0.01	-0.38	-0.58	-0.3	-0.49	-0.55	0.43	-0.4	-0.08	-0.08	-0.11	0.61	0.6		-0.07	0.79	-0.1
Common Stock Shares Outstanding	0.71	0.44	0.35	0.58	0.69	0.63	-0.92	0.25	0.06	-0.44	0.27	0.08	0.76	0.41	0.74	0.29	0.28	0.99	-0.23	-0.21	0.68	0.65	-0.07		-0.16	-0.16
Non Current Liabilities Total	0.16	-0.39	-0.58	-0.79	-0.64	-0.74	0.37	-0.43	0.33	-0.08	-0.48	-0.66	-0.6	-0.64	-0.75	0.56	-0.5	-0.18	-0.41	-0.44	0.33	0.35	0.79	-0.16		-0.44
Property Plant And Equipment Gross	-0.08	0.13	0.59	0.33	0.33	0.31	-0.09	0.29	-0.05	0.45	-0.06	0.0	0.26	0.14	0.3	-0.19	-0.05	-0.13	1.0	1.0	-0.1	-0.08	-0.1	-0.16	-0.44

Click cells to compare fundamentals

Aileron Therapeutics Account Relationship Matchups

Aileron Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	26.5M	16.3M	48.5M	22.0M	119.3M	125.3M
Other Current Liab	352K	2.2M	3.2M	1.6M	3.1M	2.4M
Total Current Liabilities	5.8M	4.0M	4.5M	3.4M	4.4M	4.5M
Total Stockholder Equity	16.0M	12.2M	43.9M	18.6M	6.9M	7.2M
Net Tangible Assets	16.0M	12.2M	43.9M	18.6M	21.4M	22.5M
Retained Earnings	(198.1M)	(219.3M)	(245.5M)	(272.8M)	(288.5M)	(302.9M)
Accounts Payable	1.5M	1.6M	1.2M	1.7M	1.2M	1.5M
Cash	5.3M	7.0M	3.6M	5.2M	17.3M	10.1M
Cash And Short Term Investments	18.3M	13.8M	45.9M	21.2M	17.3M	25.2M
Short Term Investments	38.9M	10.1M	13.0M	6.8M	42.3M	16.0M
Capital Surpluse	184.8M	188.1M	214.1M	231.4M	266.1M	279.4M
Other Current Assets	1.2M	1.9M	2.2M	606K	928K	1.1M
Other Stockholder Equity	214.1M	231.4M	289.3M	291.4M	204.0M	171.5M
Total Liab	10.4M	4.2M	4.6M	3.4M	112.4M	118.0M
Total Current Assets	19.6M	16.3M	48.2M	21.9M	18.3M	26.4M
Property Plant Equipment	6.4M	15K	280K	110K	126.5K	120.2K
Property Plant And Equipment Net	6.4M	15K	280K	110K	19K	18.1K
Net Debt	(279K)	(6.7M)	(3.4M)	(5.2M)	74.1M	77.8M
Non Current Assets Total	6.9M	15K	304K	134K	101.0M	106.1M
Non Currrent Assets Other	694K	1.2M	568K	24K	2.2M	2.3M
Common Stock Shares Outstanding	1.2M	1.7M	4.4M	4.5M	4.6M	4.8M
Liabilities And Stockholders Equity	26.5M	16.3M	48.5M	22.0M	119.3M	125.3M
Non Current Liabilities Total	4.6M	219K	69K	1.8M	108.0M	113.4M
Property Plant And Equipment Gross	6.4M	15K	492K	380K	377K	358.2K
Accumulated Other Comprehensive Income	7K	(2K)	(13K)	(48K)	(63K)	(66.2K)
Net Invested Capital	16.0M	12.5M	43.9M	18.6M	6.9M	6.5M
Net Working Capital	13.7M	12.4M	43.7M	18.5M	13.9M	18.9M
Short Long Term Debt Total	5.0M	387K	162K	33K	91.5M	96.0M
Capital Lease Obligations	5.0M	0.0	162K	33K	48K	45.6K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:

How To Invest In Aileron

Details

Is Aileron Stock a good investment?

Details

What is Aileron Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Aileron Stock analysis

When running Aileron Therapeutics' price analysis, check to measure Aileron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aileron Therapeutics is operating at the current time. Most of Aileron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aileron Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aileron Therapeutics' price. Additionally, you may evaluate how the addition of Aileron Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Aileron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.42)

Return On Assets

(0.20)

Return On Equity

(0.34)

The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aileron Property Plant And Equipment Gross vs Net Debt Analysis

Property Plant And Equipment Gross vs Net Debt

Property Plant And Equipment Gross vs Net Debt Correlation Analysis

Correlation Coefficient

Property Plant And Equipment Gross

Net Debt

Aileron Therapeutics fundamental ratios Correlations

Aileron Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aileron Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Aileron Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 1.0	Property Plant Equipment
Property Plant And Equipment Gross	+ 1.0	Property Plant Equipment
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Capital Surpluse	+ 0.99	Other Liab

Common Stock	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Other Stockholder Equity	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Other Liab
Retained Earnings	- 0.81	Net Tangible Assets